NRx Pharmaceuticals Posts Wider Q2 Loss, Misses Revenue Estimates
NRx Pharmaceuticals reported an adjusted Q2 loss of $0.18 per share, worse than the $0.09 loss expected, and revenue came in below estimates.
NRXP
NRx Pharmaceuticals, Inc. (NRXP) reported an adjusted second-quarter loss of $0.18 per share, compared with the Zacks Consensus Estimate of a $0.09 loss. The result was narrower than the adjusted loss of $0.98 per share recorded in the same period a year earlier.
The company also missed revenue estimates for the quarter. The reported earnings figures are adjusted for non-recurring items.
Source: FXStreet Forex News